Analysis of the association between resolution of disseminated intravascular coagulation (DIC) and treatment outcomes in post-marketing surveillance of thrombomodulin alpha for DIC with infectious disease and with hematological malignancy by organ failure

Table 4 Relations between DIC resolution and treatment outcome in DIC with hematological malignancy

Group	Underlying disease	OS, % (n)		κ
Group	Underlying disease	DIC resolution	DIC non-resolution	Point estimate	95% CI, [lower, upper] limits
0	AML	88.1 (104)	62.0 (57)	0.276 ± 0.062	[0.155, 0.397]
1	APL	98.6 (73)	67.9 (36)	0.339 ± 0.071	[0.200, 0.478]
2	ALL	95.3 (61)	70.4 (19)	0.301 ± 0.105	[0.096, 0.506]
3	CML	85.7 (6)	100.0 (4)	−0.170 ± 0.149	[− 0.462, 0.122]
4	CLL	66.7 (4)	50.0 (1)	0.147 ± 0.347	[−0.538, 0.823]
5	MDS	82.4 (14)	36.4 (4)	0.467 ± 0.172	[0.131, 0.804]
6	MM	100.0 (6)	55.6 (5)	0.390 ± 0.177	[0.044, 0.736]
7	ML	90.0 (36)	48.0 (24)	0.400 ± 0.086	[0.232, 0.568]

The degree of accordance between DIC resolution and treatment outcome according to the underlying disease of hematological malignancy was analyzed by κ coefficient in DIC with hematological malignancy
ALL acute lymphoid leukemia, AML acute myeloid leukemia, APL acute promyelocytic leukemia, CI confidence interval, CLL chronic lymphocytic leukemia, CML chronic myeloid leukemia, DIC disseminated intravascular coagulation, MDS myelodysplastic syndromes, ML malignant lymphoma, MM multiple myeloma, OS overall survival

ISSN: 1477-9560